Breaking News

Tweet TWEET

Harvard Bioscience Appoints Yoav Sibony as VP Global Sales

Harvard Bioscience Appoints Yoav Sibony as VP Global Sales

More Than 15 Years Global Sales Experience to Help Company Increase Growth
Worldwide

HOLLISTON, Mass., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range
of tools to advance life science research and regenerative medicine, announced
that it has hired Yoav Sibony, a veteran sales manager, as Harvard
Bioscience's Vice President of Global Sales, a newly created position,
effective October 21.

Jeffrey A. Duchemin, Chief Executive Officer of Harvard Bioscience, commented,
"Expanding the Company's sales initiatives worldwide is crucial to our
continuing growth. In order to take maximum advantage of the opportunities in
our market, it is vital that we implement a far-reaching global sales
strategy. To meet this challenge, we have created the new position of Vice
President of Global Sales. Having worked with Yoav in the past, and knowing
firsthand of his long and impressive track record of sales management
experience, I am confident that he will help Harvard Bioscience attain the
next level of growth. I look forward to collaborating with him as the Company
expands its global footprint."

Prior to joining Harvard Bioscience, Mr. Sibony, age 42, served as Global
Sales Effectiveness Manager at Corning Life Sciences, a division of Corning
Inc. In this role, he oversaw global business operations and strategy
development for this approximately $800 million division. Prior to this, from
2002 to 2012, he served in progressive positions at the medical technology
company Becton, Dickinson & Company; as Regional Business Manager at BD
Biosciences Discovery Labware, he oversaw 12 sales territories with combined
value of $45 million. Mr. Sibony holds an M.B.A. from Pacific Lutheran
University and earned a bachelor of business administration degree from Baruch
College-City University of New York.

Yoav Sibony stated, "Harvard Bioscience's reputation as one of the pre-eminent
life science research tools companies in the United States will serve as a
major foothold as the Company seeks to expand its worldwide presence. I
believe that with its range of products there is a considerable opportunity
for growth as Harvard Bioscience expands its geographical reach. I look
forward to serving as Vice President of Global Sales and working with Harvard
Bioscience's management as the Company moves ahead."

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research and regenerative medicine.
Our products are sold to thousands of researchers in over 100 countries
primarily through our 850 page catalog (and various other specialty catalogs),
our website, through distributors, including GE Healthcare, Thermo Fisher
Scientific and VWR, and via our field sales organization. HBIO has sales and
manufacturing operations in the United States, the United Kingdom, Germany,
Sweden and Spain with additional facilities in France and Canada. For more
information, please visit our website at www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6426

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are
made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements include
statements relating to, among other things, the appointment of Mr. Yoav Sibony
as Harvard Bioscience's Vice President of Global Sales. These statements
involve risks and uncertainties, including among other things, market
conditions that may cause results to differ materially from the statements set
forth in this press release. The forward-looking statements in this press
release speak only as of the date of this press release. Harvard Bioscience
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in its
expectations with regard thereto or any changes in the events, conditions or
circumstances on which any such statement is based.

For investor inquiries, please call (508) 893-8066. Press releases may be
found on our web site.

CONTACT: Jeffrey A. Duchemin
         Chief Executive Officer
         Tel: (508) 893-8999
        
         Investor Relations:
         Dian Griesel Int'l.
         Cheryl Schneider
         (212) 825-3210
        
         Public Relations:
         Dian Griesel Int'l.
         Susan Forman or Laura Radocaj
         (212) 825-3210

Harvard Bioscience, Inc. Logo